174 related articles for article (PubMed ID: 36551563)
1. Increased MARCKS Activity in BRAF Inhibitor-Resistant Melanoma Cells Is Essential for Their Enhanced Metastatic Behavior Independent of Elevated WNT5A and IL-6 Signaling.
Yadav V; Jobe N; Satapathy SR; Mohapatra P; Andersson T
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551563
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.
Mohapatra P; Prasad CP; Andersson T
Mol Oncol; 2019 Feb; 13(2):480-494. PubMed ID: 30582770
[TBL] [Abstract][Full Text] [Related]
3. WNT5A-Induced Activation of the Protein Kinase C Substrate MARCKS Is Required for Melanoma Cell Invasion.
Mohapatra P; Yadav V; Toftdahl M; Andersson T
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32033033
[TBL] [Abstract][Full Text] [Related]
4. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
[TBL] [Abstract][Full Text] [Related]
5. Reduced WNT5A signaling in melanoma cells favors an amoeboid mode of invasion.
Jobe NP; Åsberg L; Andersson T
Mol Oncol; 2021 Jul; 15(7):1835-1848. PubMed ID: 33969605
[TBL] [Abstract][Full Text] [Related]
6. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
7. Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.
Bonfill-Teixidor E; Iurlaro R; Handl C; Wichmann J; Arias A; Cuartas I; Emmenegger J; Romagnani A; Mangano L; Lorber T; Berrera M; Godfried Sie C; Köchl F; Eckmann J; Feddersen R; Kornacker M; Schnetzler G; Cicuendez M; Cordero E; Topczewski TE; Ferres-Pijoan A; González J; Martínez-Ricarte F; Muñoz-Couselo E; Tabernero J; Bischoff JR; Pettazzoni P; Seoane J
Cancer Res; 2022 Jul; 82(14):2552-2564. PubMed ID: 35584009
[TBL] [Abstract][Full Text] [Related]
8. Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?
Prasad CP; Mohapatra P; Andersson T
Cancers (Basel); 2015 Sep; 7(3):1900-24. PubMed ID: 26393652
[TBL] [Abstract][Full Text] [Related]
9. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
10. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
[TBL] [Abstract][Full Text] [Related]
11. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.
Sandri S; Watanabe LRM; Oliveira EA; Faião-Flores F; Migliorini S; Tiago M; Felipe-Silva A; Vazquez VL; da Costa Souza P; Consolaro MEL; Campa A; Maria-Engler SS
Pharmacol Res; 2020 Sep; 159():104998. PubMed ID: 32535222
[TBL] [Abstract][Full Text] [Related]
13. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
[TBL] [Abstract][Full Text] [Related]
14. BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors.
Misek SA; Foda BM; Dexheimer TS; Akram M; Conrad SE; Schmidt JC; Neubig RR; Gallo KA
Front Oncol; 2022; 12():766794. PubMed ID: 35444937
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 drives melanoma cell motility through p38α-MAPK-dependent up-regulation of WNT5A expression.
Linnskog R; Jönsson G; Axelsson L; Prasad CP; Andersson T
Mol Oncol; 2014 Dec; 8(8):1365-78. PubMed ID: 24954857
[TBL] [Abstract][Full Text] [Related]
16. BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.
Atay C; Kwak T; Lavilla-Alonso S; Donthireddy L; Richards A; Moberg V; Pilon-Thomas S; Schell M; Messina JL; Rebecca VW; Xiao M; Tan J; Zhang G; Weber JS; Herlyn M; Sarnaik AA; Gabrilovich DI
Clin Cancer Res; 2019 May; 25(9):2783-2794. PubMed ID: 30765391
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.
Wichmann J; Rynn C; Friess T; Petrig-Schaffland J; Kornacker M; Handl C; Emmenegger J; Eckmann J; Herting F; Frances N; Hunziker D; Krummenacher D; Rüttinger D; Ribeiro A; Bacac M; Brigo A; Hewings DS; Dummer R; Levesque MP; Schnetzler G; Martoglio B; Bischoff JR; Pettazzoni P
Clin Cancer Res; 2022 Feb; 28(4):770-780. PubMed ID: 34782366
[TBL] [Abstract][Full Text] [Related]
18. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
19. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.
Chan MM; Haydu LE; Menzies AM; Azer MW; Klein O; Lyle M; Clements A; Guminski A; Kefford RF; Long GV
Cancer; 2014 Oct; 120(20):3142-53. PubMed ID: 24985732
[TBL] [Abstract][Full Text] [Related]
20. BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma.
Gebhardt K; Edemir B; Groß E; Nemetschke L; Kewitz-Hempel S; Moritz RKC; Sunderkötter C; Gerloff D
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34063443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]